eLetters

131 e-Letters

published between 2005 and 2008

  • Comment on Lack of efficacy of rituximab in refractory wegener's granulomatosis
    Daman M Langguth

    Dear Editor

    Aries et al. demonstrate in their study, the lack of response of granulomatous disease in Wegener's granulomatosis to rituximab. From my reading of the paper, this agent was given every fourth week. This is not how this agent is usually prescribed, ie usually given as weekly pulses for four weeks. Despite this, Bcell numbers were depleted in the peripheral blood, though I would doubt at this low dose...

    Show More
  • Pre-treatment screening takes place before anti-TNF is prescribed
    Harald Erwin Vonkeman

    Dear Editor

    In their article: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (and likewise in their subsequent article: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists) Askling et al. compare occurrence rates for malignancies between different cohorts...

    Show More
  • Whiplash a systemic disease?
    Jerrold M. Gorski

    Dear Editor,

    Dr Ferrari has suggested that Whiplash Associated Disorders (WAD), is a systemic illness in the September Annals of Rheumatic Disesases[1], rather than an anatomically defineable lesion. They correctly quote that in 90% of patients with WAD no pathology can be found. Dr Ferrari reaches his conclusion from the acute subjective symptoms that describes involvement of multiple systems. It is not too surpr...

    Show More
  • Author's reply to: Expensive antirheumatic drugs
    Nick Bansback

    Dear Editor

    We very much welcome the thoughts of Drs Geborek and Saxne on our recent article,[1] and agree that a scientific approach should be taken to the synthesis of evidence in decision models. Our analysis is not the last word but rather the first decision analysis of adalimumab. The contention stems from the limitations in the evidence base. In this regard, to wait for all the evidence to be collected (possibly m...

    Show More
  • Autoantibodies and TNF-alpha blockade
    Marco Fusconi

    Dear Editor,

    We read with interest the paper of Eriksson et al.[1], concluding that infliximab, but not etanercept, induces anti dsDNA antibodies in patients with rheumatoid arthritis (RA). Since conflicting data[2-6] are being published about the autoantibody profile during anti TNF-alpha treatment, we report our experience in a small, but closely followed-up, cohort of patients with RA, which is not fully conco...

    Show More
  • SLE and NHL - Is there a common genetic link?
    Prasanta Padhan

    Dear Editor,

    An association has been made between systemic lupus erythematosus (SLE) and NHL. A common genetic aetiology is suggested by the observation of a marked over representation of lymphoma cases in families with SLE. Likewise, families have been described with both lymphoma and SLE. A tumour suppressor gene PTEN may link the two disorders via a defective apoptosis pathway to eliminate hyperactive B and T cells...

    Show More
  • Can glucosamine work in osteoarthritis? And chondroitin sulphate?
    Bernard G Bannwarth

    Dear Editor,

    Methodological flaws of numerous positive industry-sponsored placebo-controlled clinical trials along with possible publication bias[1] raised the question of whether orally administered glucosamine therapy does work in osteoarthritis (OA)[2]. Scepticism increased after more recent independent investigations failed to demonstrate efficacy[3-6]. In light of the study by Biggee and colleagues[7] which sho...

    Show More
  • Authors' reply to Klauser et al.
    Lene Terslev

    Dear Editor,

    We thank Dr Klauser and colleagues for their comments to our paper "Ultrasound findings in healthy joints using two different contrast media".

    We would like to take the opportunity to respond to their comments.

    Please bear in mind the findings that made us perform this study: In the literature, the injection of contrast lead to more vessels being visualised in inflamed joints while no...

    Show More
  • Re: Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patient
    Mart Mannik

    Dear Editor

    Methodological problems in the detection of IgG antibodies to glucose -6-phosphate isomerase in serum and synovial fluid from patients with inflammatory arthritis.

    Examination of the methods used by M Schaller et al in their article on the detection of IgG antibodies to glucose-6-phosphate isomerase (GPI) in patients with inflammatory arthritis (1) revealed serious deficiencies.

    The a...

    Show More
  • Expensive antirheumatic drugs
    Pierre Geborek

    Dear Editor

    The article "Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden" by Bansbeck, Brennan, and Ghatnekar [1] deals with an important subject, i.e. is it justifiable from a cost-effectiveness point of view to use tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA).

    We acknowledge that the authors have used data from...

    Show More

Pages